Related Experiment Video
Updated: Mar 28, 2026
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy
Massimo Bottini1, Kunal Bhattacharya2, Bengt Fadeel2
1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; Inflammatory and Infectious Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Abstract:
Cartilage undergoes drastic structural changes during the development of osteoarthritis and cannot heal itself due to a defective chondrocyte response. Thus, much effort has been invested in the development of disease modifying drugs able to block key mediators within the cartilage matrix and biochemical pathways inside chondrocytes. However, the delivery of therapeutic agents into cartilage is ineffective. This has led to the use of cartilage-targeted nanodrugs to accumulate therapeutic agents into specific cartilage sub-compartments. This review will describe the nanodrugs targeted to specific components of cartilage matrix to generate drug reservoirs within the cartilage. The nanodrugs used as chondrocyte-specific gene delivery systems are also described. Although the use of cartilage-targeted nanodrugs in osteoarthritis is still in its infancy, these studies lay the foundation for the development of novel approaches for preventing the progression of cartilage breakdown and improving the quality of life of patients with osteoarthritis.
From The Clinical Editor:
Osteoarthritis is a degeneration of joint cartilage, which affects a large number of aging people. Current therapy for disease modification is often suboptimal. Recent research in nanomedicine has led to the design and use of nanodrugs with the aim to help reverse the disease process. In this comprehensive review, the authors described and discussed various nanodrugs in the hope that newer drugs could be discovered in the future.
Insights
Cartilage-targeted nanodrugs offer a promising approach to treat osteoarthritis by delivering therapeutic agents directly into cartilage. This strategy aims to improve drug accumulation and overcome current treatment limitations for cartilage degeneration.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Osteoarthritis Research
Background:
- Osteoarthritis (OA) is a degenerative joint disease affecting aging populations, with current disease-modifying therapies being suboptimal.
- Cartilage's limited self-healing capacity, due to defective chondrocyte response, necessitates novel therapeutic strategies.
- Nanomedicine has emerged, focusing on nanodrug development to potentially reverse OA progression.
Purpose of the Study:
- To review cartilage-targeted nanodrugs for osteoarthritis treatment.
- To discuss nanodrugs designed to accumulate therapeutic agents within cartilage matrix and chondrocytes.
- To explore nanodrugs as chondrocyte-specific gene delivery systems.
Main Methods:
- Review of existing literature on nanodrugs for osteoarthritis.
- Analysis of nanodrug strategies targeting cartilage matrix components.
- Examination of nanodrugs utilized for chondrocyte-specific gene delivery.
Main Results:
- Nanodrugs can be targeted to specific cartilage matrix components, creating localized drug reservoirs.
- Chondrocyte-specific gene delivery systems using nanodrugs are being developed.
- Current applications of cartilage-targeted nanodrugs in OA are in early stages.
Conclusions:
- Cartilage-targeted nanodrugs represent a foundational development for novel OA therapies.
- These approaches hold potential for preventing cartilage breakdown and enhancing patient quality of life.
- Further research is needed to fully realize the therapeutic potential of nanodrugs in osteoarthritis.
